Amyris Reports Q2 Revenues

Amyris, Inc., which owns consumer brands like Biossance and Pipette and is a supplier of natural ingredients, today announced financial results for its second quarter ended June 30, 2021.
 
Total revenue of $52.3 million included record underlying and consumer revenue and included $10 million of proceeds resulting from the Reb M sweetener transaction. Total underlying revenue (product and collaboration revenue) increased 41% to $42.3 million compared to Q2 2020 revenue. It was driven by a 59% increase in consumer sales, and a 25% increase in ingredient sales. 
 
Amyris said Biossance doubled its revenue compared to the prior year quarter. Direct-to-consumer sales through Biossance.com remained strong. Internationally, Biossance experienced strong growth, particularly in southeast Asia and Australia. 
 
Pipette, its clean baby and family care brand, delivered strong quarterly revenue, noted Amyris. Brand performance in Target stores was exceptional with Pipette being recognized as a leading new brand in baby and homecare categories. Amyris noted that Pipette recently finalized agreements to launch its bestselling items through multiple retail channels including Rite Aid, Wakefern, Wegmans, KeHE and Kroger.com in 2021, and in 7,000 Walgreens stores during the first half of 2022.  Direct-to-consumer sales through Pipettebaby.com and Amazon continued to grow during the second quarter and are expected to benefit from expanded retail presence in the future.
 
During the second quarter, Amyris continued to prepare for the upcoming Q3 launches of new consumer brands— Rose, Inc., JVN, Terasana and Olika, which are all expected to generate new revenue during the second half of 2021.  The company also recently announced plans to create a menopause wellness personal care brand.
 
“With Q2 we completed another quarter of strong strategic and operational execution,” said John Melo, president and CEO. “We delivered record underlying revenue driven by record consumer revenue while significantly improving margins year-over-year. Two of our homegrown clean beauty brands, Biossance and Pipette, delivered record revenue with Biossance doubling revenue versus the prior year quarter. The performance of these brands is evidence of the rapidly growing consumer demand for high performance, affordable, and sustainable clean beauty products. In addition to our reported revenue, we had sales of $2.4 million that did not make the quarter cutoff. During Q2, we made significant efforts and investments in marketing and supply chain for the Q3 launch of our new brands: Rose Inc., JVN, Terasana and Olika which will add significant new revenue to our consumer portfolio in the second half.”
 
Second quarter ingredient revenue increased 30% sequentially, and 25% versus the prior year quarter. Q2 saw record sales revenue of squalane, said the company.
 
Melo noted that the company is “making good progress” with the construction of its new Brazil ingredients manufacturing plant in Barra Bonita and expects to complete construction by the end of this year with production to commence in early 2022.